533 related articles for article (PubMed ID: 1696012)
21. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages.
Murphy KM; Sweet MJ; Ross IL; Hume DA
J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418
[TBL] [Abstract][Full Text] [Related]
22. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.
Scala G; Ruocco MR; Ambrosino C; Mallardo M; Giordano V; Baldassarre F; Dragonetti E; Quinto I; Venuta S
J Exp Med; 1994 Mar; 179(3):961-71. PubMed ID: 8113688
[TBL] [Abstract][Full Text] [Related]
23. TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation.
Taylor JP; Pomerantz R; Bagasra O; Chowdhury M; Rappaport J; Khalili K; Amini S
EMBO J; 1992 Sep; 11(9):3395-403. PubMed ID: 1505523
[TBL] [Abstract][Full Text] [Related]
24. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.
Chen H; He J; Fong S; Wilcox G; Wood C
J Virol; 2000 Mar; 74(6):2703-13. PubMed ID: 10684286
[TBL] [Abstract][Full Text] [Related]
25. Molecular approaches to inhibit HIV-1 tat expression and functions.
Grossi MP; Caputo A; Zucchini S; Bozzini R; Marconi PC; Manservigi R; Barbanti-Brodano G; Balboni PG
Year Immunol; 1993; 7():199-204. PubMed ID: 8396820
[No Abstract] [Full Text] [Related]
26. Effect of the position of TAR on transcriptional activation by HIV-1 Tat in vivo.
Wright S; Luccarini C
J Mol Biol; 1996 Oct; 263(1):1-7. PubMed ID: 8890908
[TBL] [Abstract][Full Text] [Related]
27. Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein.
Kamine J; Subramanian T; Chinnadurai G
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8510-4. PubMed ID: 1924310
[TBL] [Abstract][Full Text] [Related]
28. Formation of a small ribonucleoprotein particle between Tat protein and trans-acting response element in human immunodeficiency virus-infected cells.
Pfeifer K; Bachmann M; Schröder HC; Weiler BE; Ugarkovic D; Okamoto T; Müller WE
J Biol Chem; 1991 Aug; 266(22):14620-6. PubMed ID: 1830589
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus Tat transactivation: induction of a tissue-specific enhancer in a nonpermissive cell line.
Remenick J; Radonovich MF; Brady JN
J Virol; 1991 Oct; 65(10):5641-6. PubMed ID: 1654461
[TBL] [Abstract][Full Text] [Related]
30. Examination of TAR-independent Trans activation by human immunodeficiency virus type 1 Tat in human glial cells.
Kim YS; Panganiban AT
J Neurosci Res; 1996 Mar; 43(6):652-66. PubMed ID: 8984195
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides.
Arzumanov A; Walsh AP; Rajwanshi VK; Kumar R; Wengel J; Gait MJ
Biochemistry; 2001 Dec; 40(48):14645-54. PubMed ID: 11724578
[TBL] [Abstract][Full Text] [Related]
32. The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription.
Rittner K; Churcher MJ; Gait MJ; Karn J
J Mol Biol; 1995 May; 248(3):562-80. PubMed ID: 7752225
[TBL] [Abstract][Full Text] [Related]
33. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.
Pearson L; Garcia J; Wu F; Modesti N; Nelson J; Gaynor R
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5079-83. PubMed ID: 2195547
[TBL] [Abstract][Full Text] [Related]
34. Human immunodeficiency virus type 1 transactivator protein, tat, stimulates transcriptional read-through of distal terminator sequences in vitro.
Graeble MA; Churcher MJ; Lowe AD; Gait MJ; Karn J
Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6184-8. PubMed ID: 8327498
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.
Lisziewicz J; Sun D; Smythe J; Lusso P; Lori F; Louie A; Markham P; Rossi J; Reitz M; Gallo RC
Proc Natl Acad Sci U S A; 1993 Sep; 90(17):8000-4. PubMed ID: 8367455
[TBL] [Abstract][Full Text] [Related]
36. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter.
Berkhout B; Gatignol A; Rabson AB; Jeang KT
Cell; 1990 Aug; 62(4):757-67. PubMed ID: 2201451
[TBL] [Abstract][Full Text] [Related]
37. Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA.
Gatignol A; Kumar A; Rabson A; Jeang KT
Proc Natl Acad Sci U S A; 1989 Oct; 86(20):7828-32. PubMed ID: 2510154
[TBL] [Abstract][Full Text] [Related]
38. Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity.
Ansari SA; Safak M; Gallia GL; Sawaya BE; Amini S; Khalili K
J Gen Virol; 1999 Oct; 80 ( Pt 10)():2629-2638. PubMed ID: 10573156
[TBL] [Abstract][Full Text] [Related]
39. A nuclear translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction.
Braddock M; Thorburn AM; Chambers A; Elliott GD; Anderson GJ; Kingsman AJ; Kingsman SM
Cell; 1990 Sep; 62(6):1123-33. PubMed ID: 2205397
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
Mukhtar M; Duan L; Bagasra O; Pomerantz RJ
Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
